Attruby net product revenue grew 134% year over year to $253.2 million.
BBP-418 faces a Nov. 27 target action date for full approval.
The company holds $1.5 billion in cash and marketable securities.
On its third-quarter 2026 earnings call, held on Oct. 29, 2026, BridgeBio (NASDAQ:BBIO) announced net product revenue of $253.2 million for Attruby, up 134% year over year. Commercial momentum across rare disease therapies expands the company's addressable market beyond $8 billion in peak annual sales.
Three things management said stand out.
Growth for Attruby, a treatment for transthyretin amyloid cardiomyopathy (a heart condition caused by misfolded proteins), stems from new patients starting therapy first rather than switching. Comparative real-world data showing reduced hospitalizations reinforce management's long-term sales projections.
Attruby U.S. net product revenue was $253.2 million, an increase of approximately 14% quarter-on-quarter and approximately 134% year-over-year.
-- Neil Kumar, Chief Executive Officer
The company expects a Food and Drug Administration decision by its Nov. 27, 2026, target action date under the Prescription Drug User Fee Act for BBP-418, a potential treatment for limb-girdle muscular dystrophy type 2I (a genetic muscle disease). Management has identified over 500 patients in the U.S.
Given their continued engagement and feedback to date, we're confident that this will be a traditional full approval and everything is looking on track for the November 27 PDUFA action date.
-- Anna Wade, Leader of Neuromuscular Franchise
Priority reviews by regulatory authorities set early target action dates for infigratinib in achondroplasia (a genetic bone growth disorder) and encaleret in autosomal dominant hypocalcemia type 1 (a rare hormone disorder). These approvals would expand the company's commercial rare disease portfolio in 2027.
On October 6, the FDA accepted our NDA with priority review and set a PDUFA date of February 4, 2027, ahead of the mid-2027 launch timing we described last quarter.
-- Matthew Outten, Chief Commercial Officer
Three commercial launches arrive within seven months, marking an operational shift. Management relies on field teams and digital tools to broaden prescriber coverage while expanding margins toward corporate breakeven.
As we look forward to next year, I see a continued margin expansion from Attruby improving operating line throughout the course of the year toward a breakeven point.
-- Thomas Trimarchi, President and Chief Financial Officer
A balance sheet holding $1.5 billion supports these launches while funding late-stage clinical development.
So put simply, we are a company with 3 launches in the next 7 months. I'm not aware of many companies our size that have been handed that type of opportunity, and we don't intend to waste it.
-- Neil Kumar, Chief Executive Officer
Before you buy stock in BridgeBio Pharma, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and BridgeBio Pharma wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $305,941!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $771,325!*
Now, it’s worth noting Stock Advisor’s total average return is 719% — a market-crushing outperformance compared to 192% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 22, 2026.
The Motley Fool recommends BridgeBio Pharma. The Motley Fool has a disclosure policy.